Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
Evaluation of the Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Patients With Infertility Using an Ultrasound Multimodal System
Tang-Du Hospital
300 participants
Sep 1, 2025
OBSERVATIONAL
Conditions
Summary
The purpose of this prospective observational cohort study is to evaluate the effect of routine clinical anticoagulant therapy on endometrial receptivity and subsequent pregnancy outcomes in women with infertility. Researchers will utilize an ultrasound multimodal system to systematically assess endometrial parameters, including thickness, morphology, peristalsis, and blood flow indices. The study aims to enroll approximately 300 infertile women aged 20 to 45 years. Participants will be observed and grouped based on whether they receive anticoagulant medications, such as aspirin or heparin sodium, as part of their standard clinical care. The study will track ultrasound-based receptivity indicators and follow up on pregnancy status and outcomes at 45 and 90 days of gestation. This study is purely observational, and all clinical treatment decisions are made independently of the study protocol.
Eligibility
Inclusion Criteria4
- Female patients aged 20 to 45 years.
- Clinically diagnosed with infertility and planning to undergo embryo transfer or monitored conception cycles.
- Patients who have complete baseline clinical data and are willing to undergo multimodal ultrasound evaluation of endometrial receptivity during the window of implantation.
- Voluntarily agreed to participate in this observational study and signed the informed consent form for data collection.
Exclusion Criteria5
- Presence of congenital uterine malformations (e.g., septate uterus, bicornuate uterus, unicornuate uterus) that significantly alter the endometrial cavity.
- Presence of untreated severe intrauterine lesions, such as submucosal fibroids, severe intrauterine adhesions, or endometrial polyps that may mechanically interfere with implantation.
- Severe underlying systemic diseases, including but not limited to severe liver or kidney dysfunction, or malignant tumors.
- Known severe bleeding disorders or strict contraindications to anticoagulant medications (for patients in the routine clinical care setting).
- Patients who are unable to cooperate with the transvaginal multimodal ultrasound examination or complete the required follow-up for pregnancy outcomes.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients receive low-dose aspirin or low molecular weight heparin (e.g., heparin sodium) purely as part of their standard clinical care. The decision to initiate, adjust, or terminate this therapy is made entirely by the attending physician based on clinical indications, strictly independent of this observational study protocol. This is tracked solely as an observational exposure.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07494877